Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 534
interventional 434
Observational 90
Registry 10

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 301
Drug|placebo 74
Biological 14
Other 8
Biological|Drug|placebo 7
Biological|Drug 6
Behavioral 4
Biological|Other 3
Biological|placebo 2
Device 2
Device|Drug 2
Diagnostic Test 2
Dietary Supplement|placebo 2
Drug|Other 2
Biological|Drug|Procedure 1
Dietary Supplement|Drug 1
Drug|Genetic 1
Drug|placebo|Procedure 1
Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
NA 83
United States 69
China 51
Korea, Republic of 27
Taiwan 14
Japan 12
Egypt 10
United States|Puerto Rico 10
France 7
Hong Kong 7
Spain 7
New Zealand 5
Singapore 5
Netherlands 4
Russian Federation 4
China|Korea, Republic of 3
India 3
Switzerland 3
Belgium 2
Canada 2
Cuba 2
Germany 2
Iran, Islamic Republic of 2
Moldova, Republic of 2
Saudi Arabia 2
United States|Canada|Hong Kong|Italy|Korea, Republic of|New Zealand|Taiwan|United Kingdom 2
United States|Canada|Hong Kong|New Zealand|United Kingdom 2
United States|France|Germany|Spain 2
United States|New Zealand 2
Algeria|Australia|Austria|Belgium|Bulgaria|Canada|Denmark|Finland|France|Germany|Greece|Ireland|Israel|Italy|Mexico|Netherlands|Norway|Poland|Portugal|Romania|Russian Federation|Saudi Arabia|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
Australia 1
Australia|Brazil|France|Poland|Russian Federation|Spain|Sweden|United Kingdom 1
Australia|Canada|France|Germany|Greece|India|Italy|Poland|Spain|Taiwan|Thailand|United Kingdom 1
Australia|Germany|Poland|Romania|Spain|Taiwan 1
Australia|Hong Kong|Korea, Republic of|New Zealand|Singapore|Taiwan|Thailand 1
Australia|Hong Kong|Korea, Republic of|New Zealand|Thailand 1
Australia|Hong Kong|Korea, Republic of|Taiwan|United Kingdom 1
Australia|New Zealand 1
Austria 1
Austria|Belgium|France|Germany|Netherlands|Spain 1
Austria|Bulgaria|Germany|Greece|Italy|Russian Federation|Spain|Turkey 1
Belgium|Brazil|France|Austria|United States|Australia|Germany|Ireland|Mexico|Poland|Spain|Sweden|United Kingdom 1
Belgium|Bulgaria|France|Georgia|Germany|Malaysia|Moldova, Republic of|Romania|Spain|Taiwan 1
Belgium|France|Germany|Italy|Poland|Romania|Spain 1
Belgium|Germany 1
Belgium|Germany|Philippines|United Kingdom 1
Brazil 1
Canada|France|Germany 1
Canada|Korea, Republic of|Taiwan 1
Canada|Netherlands 1
China|France|Korea, Republic of|Singapore|Taiwan|Thailand|United States|Australia|Canada 1
China|Hong Kong|Japan|Korea, Republic of|Philippines|Singapore 1
China|Korea, Republic of|Singapore 1
China|Netherlands 1
China|Netherlands|Poland|Romania|Turkey 1
China|United States|Korea, Republic of|Singapore|Taiwan 1
Denmark 1
France|Georgia|Moldova, Republic of 1
France|Germany|Greece|Italy|Spain 1
France|Germany|Italy|Netherlands|Poland|Romania|Spain 1
France|Germany|Netherlands 1
France|United States|Australia|Bulgaria|Canada|Czech Republic|Germany|Greece|Italy|Netherlands|New Zealand|Poland|Spain|Turkey|United Kingdom 1
Germany|Hong Kong|Korea, Republic of|New Zealand|Singapore|United Kingdom 1
Germany|Poland|Spain 1
Germany|Poland|Sweden|United Kingdom 1
Germany|Russian Federation 1
Germany|United States|Australia|Canada|France|Hong Kong|New Zealand|Poland|Singapore|Taiwan|United Kingdom 1
Guadeloupe 1
Hong Kong|Korea, Republic of 1
Hong Kong|Korea, Republic of|Singapore|Taiwan|Vietnam 1
Hong Kong|Singapore|Taiwan|Thailand 1
Israel 1
Israel|United States|Argentina|Australia|Belgium|Brazil|Canada|France|Germany|India|Korea, Republic of|Malaysia|Mexico|Poland|Puerto Rico|Singapore|Spain|Sweden|Taiwan|Thailand|United Kingdom 1
Italy 1
Korea, Republic of|Moldova, Republic of|New Zealand|Thailand|Ukraine 1
Mauritius|Moldova, Republic of|New Zealand|United Kingdom 1
Poland 1
Puerto Rico 1
Sweden 1
United Kingdom 1
United Kingdom|Australia|Canada|Israel|New Zealand|Spain 1
United States|Argentina|Australia|Brazil|France|Italy|Korea, Republic of|Spain|Taiwan 1
United States|Argentina|Australia|Canada|France|Israel|Italy|Poland|Puerto Rico|Russian Federation|Spain|United Kingdom 1
United States|Argentina|Belgium|Canada|Germany|Greece|India|Israel|Korea, Republic of|Poland|Romania|Russian Federation|Taiwan|United Kingdom 1
United States|Australia|Austria|Canada|Czech Republic|France|Germany|India|Israel|Italy|Poland|Puerto Rico|Romania|Spain|United Kingdom 1
United States|Australia|Belgium|Germany|Italy|Malaysia|Romania|Russian Federation|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Australia|Belgium|Germany|Puerto Rico|Spain|Taiwan 1
United States|Australia|Brazil|Canada|China|France|Germany|Israel|Korea, Republic of|New Zealand|Poland|Puerto Rico|Singapore|Switzerland|Taiwan|Thailand|United Kingdom 1
United States|Australia|Bulgaria|Canada|Czech Republic|France|Germany|Greece|Italy|Netherlands|New Zealand|Poland|Spain|Turkey|United Kingdom 1
United States|Australia|Canada|China|Czech Republic|France|Germany|Hong Kong|India|Israel|Italy|Korea, Republic of|New Zealand|Poland|Puerto Rico|Singapore|Spain|Taiwan|Thailand|Turkey|United Kingdom 1
United States|Australia|Canada|China|France|Israel|New Zealand|Singapore|Taiwan|Thailand|United Kingdom 1
United States|Australia|Canada|France|Germany|Greece|Hong Kong|India|Italy|Korea, Republic of|Netherlands|Poland|Portugal|Romania|Singapore|Spain|Taiwan|Turkey|United Kingdom 1
United States|Australia|Canada|France|Germany|New Zealand|Puerto Rico|Spain|United Kingdom 1
United States|Australia|Canada|New Zealand|United Kingdom 1
United States|Australia|China|Hong Kong|Korea, Republic of|New Zealand|United Kingdom 1
United States|Austria|Belgium|Canada|Czech Republic|France|Germany|Italy|Poland|Spain|United Kingdom 1
United States|Belgium|Canada|Germany|Japan|Puerto Rico|Russian Federation|Spain|United Kingdom 1
United States|Belgium|Canada|Hong Kong|India|Korea, Republic of|New Zealand|Romania|Russian Federation|Taiwan 1
United States|Belgium|Denmark 1
United States|Belgium|Germany|Puerto Rico|Spain 1
United States|Bulgaria|Canada|Czechia|France|Greece|Hungary|Ireland|Israel|Italy|Poland|Portugal|Puerto Rico|Romania|Russian Federation|Spain|Taiwan|United Kingdom|Vietnam 1
United States|Bulgaria|France|Poland|Romania|Spain|Turkey 1
United States|Canada 1
United States|Canada|France|Germany|Greece|Italy|Poland|Singapore|Spain|Taiwan|Turkey 1
United States|Canada|Germany|Greece|Italy|Korea, Republic of|Poland|Puerto Rico|Spain|Sweden 1
United States|Canada|Germany|Poland|United Kingdom 1
United States|Canada|Hong Kong|Indonesia|Philippines|Singapore|Taiwan|Thailand 1
United States|Canada|Hong Kong|Italy|Korea, Republic of|Spain|Taiwan|United Kingdom 1
United States|Canada|Italy|Korea, Republic of|Netherlands|New Zealand 1
United States|Canada|Italy|Korea, Republic of|New Zealand|Romania 1
United States|Canada|New Zealand 1
United States|France 1
United States|France|Germany|New Zealand|Spain 1
United States|France|Puerto Rico 1
United States|India|Korea, Republic of|Romania|Taiwan 1
United States|Korea, Republic of|Spain|Thailand|Turkey|United Kingdom 1
United States|United Kingdom 1

Sites per Study

Site_count Study_Count
1 222
2 29
3 10
4 12
5 6
6 9
7 4
8 10
9 6
10 7
11 8
12 7
13 4
14 7
15 7
16 5
18 5
19 6
20 2
21 8
22 1
23 1
24 4
25 4
26 2
27 1
28 3
30 1
31 1
32 3
33 1
34 2
35 1
37 1
38 4
39 4
40 1
41 1
42 1
43 2
44 1
45 1
48 3
52 1
54 1
55 1
60 1
74 1
80 1
87 1
97 1
100 1
102 1
113 1
114 1
159 1
165 1
171 1
187 1

Phase

Phase Study_Count
Phase 2 124
Phase 3 115
Phase 4 84
Phase 1 46
N/A 35
Phase 1/Phase 2 16
Phase 2/Phase 3 13
Early Phase 1 1

Number of Arms

Number_of_Arms Count_of_Studies
1 89
2 154
3 55
4 37
5 13
6 12
7 5
8 5
9 2
11 2
12 4
14 1
22 2
NA 53

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 52 13.000 8.0000 9.00000 5.0000 40.0000 10.0000 10.0000
1st Qu. 52 34.250 24.7500 26.00000 39.0000 100.0000 104.0000 60.0000
Median 52 99.500 34.5000 37.00000 70.0000 121.0000 187.0000 122.0000
Mean 52 2449.588 46.8913 43.64286 108.1463 260.9231 359.8532 266.1928
3rd Qu. 52 150.000 59.5000 60.75000 125.0000 318.0000 480.0000 229.5000
Max. 52 50000.000 130.0000 104.00000 765.0000 946.0000 5000.0000 2200.0000

Trial Group Type

group_type Group_Count
Experimental 786
Active Comparator 175
Placebo Comparator 58
NA 53
No Intervention 29
Other 20

Intervention Model

intervention_model Study_Count
Parallel Assignment 293
Single Group Assignment 119
NA 12
Crossover Assignment 5
Sequential Assignment 4
Factorial Assignment 1

Primary Purpose

primary_purpose Study_Count
Treatment 403
NA 8
Diagnostic 6
Other 5
Basic Science 4
Prevention 4
Health Services Research 2
Screening 2

Observational Studies

Studies by Country

Country Study_Count
NA 16
China 15
Korea, Republic of 7
United States 7
Taiwan 6
Netherlands 4
France 3
Hong Kong 3
Russian Federation 3
Australia 2
Germany 2
India 2
Israel 2
Italy 2
Spain 2
Austria 1
Belgium|France|Germany|Netherlands|Switzerland|United Kingdom 1
China|Japan 1
China|United States|Argentina|Brazil|Canada|Colombia|Czechia|France|Germany|Greece|India|Italy|Korea, Republic of|Mexico|Philippines|Poland|Portugal|Romania|Russian Federation|Singapore|Spain|Taiwan|Thailand|Turkey 1
Colombia 1
Egypt 1
France|Austria|Belgium|Greece|Israel|Italy|Poland|Portugal|Switzerland 1
India|United States|Argentina|Brazil|China|France|Greece|Italy|Peru|Philippines|Poland|Romania|Russian Federation|Singapore|Spain|Taiwan|Thailand|United Kingdom 1
Japan 1
Mexico 1
Puerto Rico 1
Senegal 1
Switzerland 1
Uzbekistan 1

Sites per Study

Site_count Study_Count
1 66
2 4
3 2
4 3
5 1
6 1
7 3
9 2
18 1
19 1
22 1
61 1
70 1
86 1
156 1
290 1

Enrollment Metrics

Measure Observational
Min 10.0000
1st Qu 87.0000
Median 253.0000
Mean 838.0667
3rd Qu 554.2500
Max 12522.0000

Observation Model

observational_model Study_Count
Cohort 61
Case-Only 12
NA 7
Case-Control 5
Other 3
Case Control 1
Defined Population, Natural History 1

Time Perspective

time_perspective Study_Count
Prospective 59
Retrospective 14
Cross-Sectional 7
Other 7
NA 2
Longitudinal, Prospective 1

Registries

Studies by Country

Country Study_Count
China 4
Korea, Republic of 3
Egypt 1
Japan 1
NA 1

Sites per Study

Site_count Study_Count
1 10

Enrollment Metrics

Measure Registries
Min 55.0
1st Qu 296.0
Median 659.0
Mean 1815.9
3rd Qu 1750.0
Max 10000.0

Registry Model

observational_model Study_Count
Cohort 7
Case-Control 1
Case-Only 1
NA 1

Time Perspective

time_perspective Study_Count
Prospective 7
Other 2
Cross-Sectional 1

Follow-up

target_duration Study_Count
10 Years 2
5 Years 2
1 Day 1
144 Weeks 1
2 Weeks 1
20 Years 1
24 Weeks 1
48 Weeks 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03373396 Impact of Chlordecone on Active Chronic Hepatitis https://ClinicalTrials.gov/show/NCT03373396 Completed Centre Hospitalier Universitaire de Pointe-a-Pitre 2015-12-21
NCT03258710 A Study of Switching From Entecavir to Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT03258710 Completed GlaxoSmithKline 2018-12-28
NCT03241641 Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir. https://ClinicalTrials.gov/show/NCT03241641 Active, not recruiting Asan Medical Center 2020-03-31
NCT03235349 Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection https://ClinicalTrials.gov/show/NCT03235349 Completed AbbVie 2018-11-15
NCT03222583 A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection https://ClinicalTrials.gov/show/NCT03222583 Completed AbbVie 2018-10-18
NCT03219216 A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection https://ClinicalTrials.gov/show/NCT03219216 Completed AbbVie 2019-03-11
NCT03188276 The Relationship Between MDSCs and NK Cells Activity of CHC Patient Treated by DAAs https://ClinicalTrials.gov/show/NCT03188276 Completed Third Affiliated Hospital, Sun Yat-Sen University 2017-05-01
NCT03180619 Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV) https://ClinicalTrials.gov/show/NCT03180619 Active, not recruiting Gilead Sciences 2019-03-27
NCT03180333 The Tolerability and Pharmacokinetics Clinical Trial of Metacavir Enteric-coated Capsules in Healthy Adult Volunteers https://ClinicalTrials.gov/show/NCT03180333 Completed Guangzhou Yipinhong Pharmaceutical CO.,LTD 2012-08-31
NCT03173599 The Safety and Tolerability of Metacavir Enteric-coated Capsules in Healthy Adult Volunteers https://ClinicalTrials.gov/show/NCT03173599 Completed Guangzhou Yipinhong Pharmaceutical CO.,LTD 2011-04-30
NCT03163849 Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients https://ClinicalTrials.gov/show/NCT03163849 Active, not recruiting Assiut University 2020-06-01
NCT03109730 Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT03109730 Completed Assembly Biosciences 2018-03-31
NCT03089944 A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis https://ClinicalTrials.gov/show/NCT03089944 Completed AbbVie 2019-07-31
NCT03069365 A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment https://ClinicalTrials.gov/show/NCT03069365 Completed AbbVie 2018-02-20
NCT03067129 A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection https://ClinicalTrials.gov/show/NCT03067129 Active, not recruiting AbbVie 2020-02-18
NCT03038113 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of RO7062931in Healthy Volunteers and Subjects With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT03038113 Completed Hoffmann-La Roche 2019-10-18
NCT03036852 Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease https://ClinicalTrials.gov/show/NCT03036852 Completed Gilead Sciences 2018-08-13
NCT03020745 A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3389404 in Chronic Hepatitis B (CHB) Subjects https://ClinicalTrials.gov/show/NCT03020745 Completed GlaxoSmithKline 2019-01-28
NCT03020095 Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan https://ClinicalTrials.gov/show/NCT03020095 Completed Ascletis Pharmaceuticals Co., Ltd. 2016-08-31
NCT03020082 Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III https://ClinicalTrials.gov/show/NCT03020082 Completed Ascletis Pharmaceuticals Co., Ltd. 2017-05-31
NCT03020004 Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II https://ClinicalTrials.gov/show/NCT03020004 Completed Ascletis Pharmaceuticals Co., Ltd. 2016-11-30
NCT03013556 Study on an Optimal Antiviral Treatment in HBeAg Positive Chronic Hepatitis B Patients https://ClinicalTrials.gov/show/NCT03013556 Recruiting Ruijin Hospital 2020-06-30
NCT02992704 Peg-interferon for Inactive Chronic Hepatitis B Carriers https://ClinicalTrials.gov/show/NCT02992704 Active, not recruiting National University Health System, Singapore 2019-08-31
NCT02991638 Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers https://ClinicalTrials.gov/show/NCT02991638 Recruiting The University of Hong Kong 2020-12-31
NCT02972723 Metformin Therapy in HCV Infection https://ClinicalTrials.gov/show/NCT02972723 Completed Nottingham University Hospitals NHS Trust 2011-09-30
NCT02971033 Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02971033 Recruiting VA Office of Research and Development 2021-03-31
NCT02908191 A Study in Healthy Volunteers and Patients With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT02908191 Completed Assembly Biosciences 2018-03-31
NCT02881008 Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT02881008 Completed Hepatera Ltd. 2014-10-04
NCT02862548 Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant https://ClinicalTrials.gov/show/NCT02862548 Active, not recruiting Gilead Sciences 2018-02-08
NCT02845401 The “HBV e-Antigen Negative Disease-Directly Offers” Study: Treatment Withdrawal in Patients With Early-Antigen Negative Chronic HBV https://ClinicalTrials.gov/show/NCT02845401 Active, not recruiting California Pacific Medical Center Research Institute 2021-11-17
NCT02838810 The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg https://ClinicalTrials.gov/show/NCT02838810 Recruiting Third Affiliated Hospital, Sun Yat-Sen University 2019-12-31
NCT02823457 VBMI to Increase Treatment Completion With MK-MK-5172/MK-8742 Among Veterans With Active Substance Use Disorders Genotype 1 Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02823457 Completed G.V. (Sonny) Montgomery VA Medical Center 2020-01-30
NCT02792088 Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues https://ClinicalTrials.gov/show/NCT02792088 Recruiting IlDong Pharmaceutical Co Ltd 2019-03-31
NCT02774837 Tenofovir Versus Tenofovir + Telbivudine for Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT02774837 Active, not recruiting National University Health System, Singapore 2020-07-31
NCT02772003 DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT02772003 Active, not recruiting National Cancer Institute (NCI) 2020-03-04
NCT02745704 The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg https://ClinicalTrials.gov/show/NCT02745704 Recruiting Third Affiliated Hospital, Sun Yat-Sen University 2019-04-30
NCT02738554 Off Treatment Durability in Chronic Hepatitis B With Good Immune Control https://ClinicalTrials.gov/show/NCT02738554 Completed The University of Hong Kong 2020-01-31
NCT02738138 A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2) https://ClinicalTrials.gov/show/NCT02738138 Completed AbbVie 2017-03-15
NCT02723084 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT02723084 Completed AbbVie 2017-01-19
NCT02707952 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT02707952 Completed AbbVie 2016-11-14
NCT02692703 A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2) https://ClinicalTrials.gov/show/NCT02692703 Completed AbbVie 2017-04-13
NCT02662712 A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II) https://ClinicalTrials.gov/show/NCT02662712 Completed Janssen Sciences Ireland UC 2018-06-29
NCT02651194 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection https://ClinicalTrials.gov/show/NCT02651194 Completed AbbVie 2016-10-31
NCT02640482 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection https://ClinicalTrials.gov/show/NCT02640482 Completed AbbVie 2016-09-30
NCT02640157 A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection https://ClinicalTrials.gov/show/NCT02640157 Completed AbbVie 2016-10-31
NCT02609659 Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT02609659 Completed AbbVie 2016-10-07
NCT02604017 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection https://ClinicalTrials.gov/show/NCT02604017 Completed AbbVie 2017-01-31
NCT02589457 Study to Compare the Safety and Pharmacokinetics of CKD-390 Tablet With Viread® Tablet https://ClinicalTrials.gov/show/NCT02589457 Completed Chong Kun Dang Pharmaceutical 2015-12-31
NCT02576314 Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients https://ClinicalTrials.gov/show/NCT02576314 Completed Humanity and Health Research Centre 2017-12-31
NCT02569710 A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir https://ClinicalTrials.gov/show/NCT02569710 Completed Alios Biopharma Inc. 2018-05-11
NCT02569372 A Phase 1 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients https://ClinicalTrials.gov/show/NCT02569372 Completed Green Cross Corporation 2017-10-12
NCT02565719 REP 2139-Mg and REP 2165-Mg Combination Therapy in Chronic Hepatitis B Infection https://ClinicalTrials.gov/show/NCT02565719 Completed Replicor Inc. 2019-05-31
NCT02932150 Tenofovir Alafenamide (TAF) in Children and Adolescents With Chronic Hepatitis B Virus Infection https://ClinicalTrials.gov/show/NCT02932150 Recruiting Gilead Sciences 2023-02-28
NCT02517528 ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis https://ClinicalTrials.gov/show/NCT02517528 Completed AbbVie 2016-09-29
NCT02517515 ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection https://ClinicalTrials.gov/show/NCT02517515 Completed AbbVie 2016-10-31
NCT02493855 Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults https://ClinicalTrials.gov/show/NCT02493855 Completed AbbVie 2016-04-30
NCT02486406 A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects https://ClinicalTrials.gov/show/NCT02486406 Active, not recruiting AbbVie 2020-11-26
NCT02482077 Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients https://ClinicalTrials.gov/show/NCT02482077 Completed Humanity and Health Research Centre 2017-12-31
NCT02468648 Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816 https://ClinicalTrials.gov/show/NCT02468648 Completed National Institutes of Health Clinical Center (CC) 2018-09-14
NCT02446717 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy https://ClinicalTrials.gov/show/NCT02446717 Completed AbbVie 2016-12-31
NCT02442284 A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT02442284 Completed AbbVie 2016-08-22
NCT02442271 A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil https://ClinicalTrials.gov/show/NCT02442271 Completed AbbVie 2016-07-04
NCT02439567 Transient Elastography to Assess Liver Fibrosis and Portal Hypertension in HCV Cirrhotic Patients Treated With New Antiviral Drugs (SPLEEN-C) https://ClinicalTrials.gov/show/NCT02439567 Completed Hospital Universitari Vall d’Hebron Research Institute 2016-07-31
NCT02401737 Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients https://ClinicalTrials.gov/show/NCT02401737 Completed Novira Therapeutics, Inc. 2016-05-18
NCT02399345 Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults https://ClinicalTrials.gov/show/NCT02399345 Completed AbbVie 2015-11-30
NCT02364336 Add-on Peginterferon Following Nucleos(t)Ide Analogue Treatment https://ClinicalTrials.gov/show/NCT02364336 Completed National Institutes of Health Clinical Center (CC) 2018-05-21
NCT02356562 A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT02356562 Completed AbbVie 2016-10-28
NCT02355951 Non-investigational Study to Evaluate Adenovirus Serotype 5 (Ad5) Neutralizing Antibodies (nAb) in Patients With Chronic Hepatitis B Virus (HBV) Mono-infection https://ClinicalTrials.gov/show/NCT02355951 Completed Transgene 2016-02-29
NCT02349048 Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection https://ClinicalTrials.gov/show/NCT02349048 Completed Janssen Research & Development, LLC 2016-02-29
NCT02339207 First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 https://ClinicalTrials.gov/show/NCT02339207 Completed Alios Biopharma Inc. 2016-05-31
NCT02332473 A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT02332473 Completed Xiamen Amoytop Biotech Co., Ltd. 2016-02-29
NCT02292719 A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT02292719 Completed AbbVie 2017-07-14
NCT02287857 Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT02287857 Recruiting Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 2019-10-31
NCT02265237 A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1) https://ClinicalTrials.gov/show/NCT02265237 Completed AbbVie 2016-07-28
NCT02263079 A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase https://ClinicalTrials.gov/show/NCT02263079 Completed Hoffmann-La Roche 2020-01-29
NCT02250807 Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT02250807 Completed Janssen R&D Ireland 2015-12-31
NCT02249988 Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT02249988 Completed Abivax S.A. 2016-12-31
NCT02243293 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection https://ClinicalTrials.gov/show/NCT02243293 Completed AbbVie 2016-10-25
NCT02243280 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection https://ClinicalTrials.gov/show/NCT02243280 Completed AbbVie 2016-02-29
NCT02224456 Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis https://ClinicalTrials.gov/show/NCT02224456 Active, not recruiting GlaxoSmithKline 2020-12-02
NCT02219503 A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis https://ClinicalTrials.gov/show/NCT02219503 Completed AbbVie 2015-06-30
NCT02219490 A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection https://ClinicalTrials.gov/show/NCT02219490 Active, not recruiting AbbVie 2021-05-12
NCT02219477 A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis https://ClinicalTrials.gov/show/NCT02219477 Completed AbbVie 2016-06-13
NCT02216422 A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection https://ClinicalTrials.gov/show/NCT02216422 Completed AbbVie 2015-12-31
NCT02216045 Effect of Camel Milk on Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02216045 Completed Mashhad University of Medical Sciences 2015-02-28
NCT02207088 Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease https://ClinicalTrials.gov/show/NCT02207088 Completed AbbVie 2016-12-06
NCT02203149 Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058) https://ClinicalTrials.gov/show/NCT02203149 Completed Merck Sharp & Dohme Corp. 2015-10-02
NCT02202473 Oxymatrine Plus Lamivudine Combination Therapy Versus Lamivudine Monotherapy for Chronic Hepatitis B Infected Subjects https://ClinicalTrials.gov/show/NCT02202473 Completed Southeast University, China 2014-02-28
NCT02195518 Tenofovir Disoproxil Fumarate (TDF) 300mg 3 Years RD Therapy Chinese Chronic Hepatitis B (CHN) CHB Multiple Nucleos(t)Ide Analogues (NAs) Failure Points Pts PH4 PMS Study https://ClinicalTrials.gov/show/NCT02195518 Completed GlaxoSmithKline 2018-08-14
NCT02174276 Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Participants With Chronic Hepatitis B (CHB) and Who Are Currently Not on Treatment https://ClinicalTrials.gov/show/NCT02174276 Completed Gilead Sciences 2016-02-17
NCT02168361 The SIM-SOF Trial for Hepatitis C https://ClinicalTrials.gov/show/NCT02168361 Completed Center For Hepatitis C, Atlanta, GA 2014-12-31
NCT02167945 A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection https://ClinicalTrials.gov/show/NCT02167945 Active, not recruiting AbbVie 2021-05-12
NCT02166047 Safety and Efficacy of GS-9620 for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Subjects https://ClinicalTrials.gov/show/NCT02166047 Completed Gilead Sciences 2016-05-31
NCT02118012 Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02118012 Completed National Institutes of Health Clinical Center (CC) 2014-03-20
NCT02115321 Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059) https://ClinicalTrials.gov/show/NCT02115321 Completed Merck Sharp & Dohme Corp. 2015-03-05
NCT02112799 Safety and Efficacy Study of NVR 3-778 in Healthy Volunteers and Hepatitis B Patients https://ClinicalTrials.gov/show/NCT02112799 Completed Novira Therapeutics, Inc. 2016-05-18
NCT02105688 An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062) https://ClinicalTrials.gov/show/NCT02105688 Completed Merck Sharp & Dohme Corp. 2015-06-10
NCT02105662 An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061) https://ClinicalTrials.gov/show/NCT02105662 Completed Merck Sharp & Dohme Corp. 2015-02-20
NCT02105467 Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060) https://ClinicalTrials.gov/show/NCT02105467 Completed Merck Sharp & Dohme Corp. 2015-02-26
NCT02094443 Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option https://ClinicalTrials.gov/show/NCT02094443 Completed Debiopharm International SA 2015-04-30
NCT02068222 A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection https://ClinicalTrials.gov/show/NCT02068222 Completed AbbVie 2015-03-31
NCT01314261 Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects https://ClinicalTrials.gov/show/NCT01314261 Completed AbbVie 2012-01-31
NCT01306617 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection https://ClinicalTrials.gov/show/NCT01306617 Completed AbbVie 2011-11-30
NCT01290965 Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients https://ClinicalTrials.gov/show/NCT01290965 Completed Scynexis, Inc. 2008-12-31
NCT01277601 Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT01277601 Completed Gilead Sciences 2014-08-31
NCT01276756 Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV) https://ClinicalTrials.gov/show/NCT01276756 Completed Cairo University 2012-11-30
NCT02023099 Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection https://ClinicalTrials.gov/show/NCT02023099 Completed AbbVie 2014-10-31
NCT03753074 Effectiveness of TAF in Reducing Clinical Events in CHB Patients Beyond Treatment Indications by Current Guidelines https://ClinicalTrials.gov/show/NCT03753074 Recruiting Asan Medical Center 2023-12-31
NCT01651403 Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection https://ClinicalTrials.gov/show/NCT01651403 Active, not recruiting Gilead Sciences 2017-08-07
NCT03357822 A Real-World Study of Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT03357822 Recruiting Tongji Hospital 2022-01-25
NCT03356834 Change of Renal Function and Bone Mineral Density in CHB Patients Switch From TDF to TAF vs. Maintaining TDF https://ClinicalTrials.gov/show/NCT03356834 Recruiting Humanity and Health Research Centre 2022-10-31
NCT02014571 Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C. https://ClinicalTrials.gov/show/NCT02014571 Completed GlaxoSmithKline 2014-07-03
NCT01997944 Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase Ib Study in Chronic Hepatitis B Patients https://ClinicalTrials.gov/show/NCT01997944 Completed Beijing Bio-Fortune Ltd. 2014-09-30
NCT01995071 A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV) https://ClinicalTrials.gov/show/NCT01995071 Completed AbbVie 2015-06-30
NCT01970904 Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients https://ClinicalTrials.gov/show/NCT01970904 Completed Debiopharm International SA 2015-03-31
NCT01951209 Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis https://ClinicalTrials.gov/show/NCT01951209 Active, not recruiting Corporal Michael J. Crescenz VA Medical Center 2018-08-31
NCT01939197 A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection https://ClinicalTrials.gov/show/NCT01939197 Completed AbbVie 2016-07-21
NCT01938625 A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation https://ClinicalTrials.gov/show/NCT01938625 Completed Janssen R&D Ireland 2015-04-27
NCT01937806 Phase 3 and Extensional Study of Besifovir https://ClinicalTrials.gov/show/NCT01937806 Active, not recruiting IlDong Pharmaceutical Co Ltd 2016-02-29
NCT01928511 Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy https://ClinicalTrials.gov/show/NCT01928511 Completed National University Health System, Singapore 2018-12-31
NCT01913431 Baracle Tab. ® Versus Baraclude Tab.® for Patients With HBeAg Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT01913431 Completed Dong-A ST Co., Ltd. 2015-11-06
NCT01911845 An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine https://ClinicalTrials.gov/show/NCT01911845 Completed AbbVie 2013-12-31
NCT01908335 A Phase â…¡ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01908335 Completed Beijing Kawin Technology Share-Holding Co., Ltd. 2013-08-31
NCT01903278 Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01903278 Completed Beijing Kawin Technology Share-Holding Co., Ltd. 2015-08-31
NCT01899092 Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01899092 Completed Tacere Therapeutics, Inc. 2016-09-30
NCT01892241 Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNA https://ClinicalTrials.gov/show/NCT01892241 Completed Third Affiliated Hospital, Sun Yat-Sen University 2012-11-30
NCT01888900 New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01888900 Completed National Institutes of Health Clinical Center (CC) 2015-11-30
NCT01887275 A Control Study to Evaluate The Efficacy And Safety of Ozone-therapy in Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT01887275 Completed Nanfang Hospital of Southern Medical University 2013-02-28
NCT01859962 Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01859962 Completed Presidio Pharmaceuticals, Inc. 2014-05-31
NCT01854697 A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before https://ClinicalTrials.gov/show/NCT01854697 Completed AbbVie 2014-11-30
NCT01854528 A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults https://ClinicalTrials.gov/show/NCT01854528 Completed AbbVie 2014-11-30
NCT01852604 Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) https://ClinicalTrials.gov/show/NCT01852604 Completed Merck Sharp & Dohme Corp. 2015-04-30
NCT01842451 A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01842451 Completed Vertex Pharmaceuticals Incorporated 2014-05-31
NCT01833533 A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection https://ClinicalTrials.gov/show/NCT01833533 Completed AbbVie 2013-12-31
NCT01817725 Hepatitis B Vaccine in Chronic Hepatitis B Patients With Low Serum HBsAg https://ClinicalTrials.gov/show/NCT01817725 Completed Chang Gung Memorial Hospital 2016-02-29
NCT01790100 A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01790100 Completed Alios Biopharma Inc. 2014-06-30
NCT01782495 A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients https://ClinicalTrials.gov/show/NCT01782495 Completed AbbVie 2016-11-02
NCT01767116 A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection https://ClinicalTrials.gov/show/NCT01767116 Completed AbbVie 2013-12-31
NCT01760122 Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT01760122 Completed Xiamen Amoytop Biotech Co., Ltd. 2015-07-31
NCT01753570 Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC) https://ClinicalTrials.gov/show/NCT01753570 Completed Mitsubishi Tanabe Pharma Corporation 2015-10-31
NCT01740791 Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-5816 in Subjects With Chronic HCV Infection https://ClinicalTrials.gov/show/NCT01740791 Completed Gilead Sciences 2014-01-31
NCT01732367 TDF VS LAM + ADV in LAM + ADV Treated LAM-resistant CHB Patients With Undetectable Hepatitis B Virus DNA https://ClinicalTrials.gov/show/NCT01732367 Completed Keimyung University Dongsan Medical Center 2016-03-31
NCT01728935 Tenofovir in Asian Chronic Hepatitis B Patients https://ClinicalTrials.gov/show/NCT01728935 Completed The University of Hong Kong 2012-11-30
NCT01726946 A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01726946 Completed Vertex Pharmaceuticals Incorporated 2014-02-28
NCT01724086 A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus https://ClinicalTrials.gov/show/NCT01724086 Completed Janssen R&D Ireland 2014-09-30
NCT01717560 Hepatitis C Treatment in Underserved Populations https://ClinicalTrials.gov/show/NCT01717560 Enrolling by invitation Weill Medical College of Cornell University 2012-12-31
NCT01716585 A Study to Evaluate Chronic Hepatitis C Infection https://ClinicalTrials.gov/show/NCT01716585 Completed AbbVie 2013-10-31
NCT01715415 A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults https://ClinicalTrials.gov/show/NCT01715415 Completed AbbVie 2013-11-30
NCT01711567 Tenofovir Disoproxil Fumarate vs. Entecavir in Chronic Hepatitis B Patients With Partial Virologic Response to Entecavir https://ClinicalTrials.gov/show/NCT01711567 Completed Korea University 2015-12-31
NCT01710501 A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038) https://ClinicalTrials.gov/show/NCT01710501 Completed Merck Sharp & Dohme Corp. 2013-11-25
NCT01708889 Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction https://ClinicalTrials.gov/show/NCT01708889 Completed Bristol-Myers Squibb 2013-02-28
NCT01704755 A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis https://ClinicalTrials.gov/show/NCT01704755 Completed AbbVie 2014-01-31
NCT01700179 Evaluation of Safety Tolerability and Antiviral Activity of ACH-0143102 Plus RBV Treatment Naive HCV GT1b Subjects https://ClinicalTrials.gov/show/NCT01700179 Completed Alexion Pharmaceuticals 2013-09-30
NCT01687270 Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant https://ClinicalTrials.gov/show/NCT01687270 Completed Gilead Sciences 2013-12-31
NCT01686789 Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4 https://ClinicalTrials.gov/show/NCT01686789 Completed King Abdulaziz Medical City 2015-08-31
NCT01685203 A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT01685203 Completed AbbVie 2014-06-30
NCT01684787 Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients https://ClinicalTrials.gov/show/NCT01684787 Completed Hospital Universitari de Bellvitge 2011-05-31
NCT01678131 Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048) https://ClinicalTrials.gov/show/NCT01678131 Completed Merck Sharp & Dohme Corp. 2013-08-27
NCT01674725 A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01674725 Completed AbbVie 2014-01-31
NCT01672983 A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT01672983 Completed AbbVie 2014-05-31
NCT01671787 A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT01671787 Completed Gilead Sciences 2013-04-30
NCT01609933 A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study https://ClinicalTrials.gov/show/NCT01609933 Completed AbbVie 2017-05-03
NCT01596517 Efficacy and Effectiveness of PegInterferon and Ribavirin in Korean Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01596517 Completed Asan Medical Center 2011-12-31
NCT01581398 Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients https://ClinicalTrials.gov/show/NCT01581398 Completed Xiamen Amoytop Biotech Co., Ltd. 2014-04-30
NCT01581138 VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C https://ClinicalTrials.gov/show/NCT01581138 Completed Vertex Pharmaceuticals Incorporated 2013-06-30
NCT01580995 Herpes Simplex Type 1 Suppression in Hepatitis C https://ClinicalTrials.gov/show/NCT01580995 Completed VA Office of Research and Development 2014-12-31
NCT01532843 Lowering Viral Load With Nucleos(T)Ide Analogues Prior to Peginterferon Treatment to Ncrease Sustained Response in CHB https://ClinicalTrials.gov/show/NCT01532843 Completed Foundation for Liver Research 2015-08-31
NCT01522625 Tenofovir in Chronic Hepatitis B With Mild ALT Elevation https://ClinicalTrials.gov/show/NCT01522625 Completed E-DA Hospital 2018-11-30
NCT01516918 A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis https://ClinicalTrials.gov/show/NCT01516918 Completed Vertex Pharmaceuticals Incorporated 2013-09-30
NCT01513941 An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1) https://ClinicalTrials.gov/show/NCT01513941 Completed Janssen-Cilag International NV 2014-03-31
NCT01509391 Keyhole Limpet Hemocyanin in Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01509391 Completed Medical University of Graz 2012-10-31
NCT01498068 Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01498068 Completed Janssen-Cilag International NV 2012-04-30
NCT01480492 Effect of Antiviral Therapy on Host Immune in Patients With Chronic Hepatitis B Virus(HBV) Infection https://ClinicalTrials.gov/show/NCT01480492 Completed Changhai Hospital 2011-10-31
NCT01480284 Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue https://ClinicalTrials.gov/show/NCT01480284 Completed GlaxoSmithKline 2013-01-31
NCT01475851 Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs https://ClinicalTrials.gov/show/NCT01475851 Completed GlaxoSmithKline 2013-06-30
NCT01471535 HBsAg Clearance in Inactive Chronic HBsAg Carriers After Interferon Treated https://ClinicalTrials.gov/show/NCT01471535 Completed Beijing Ditan Hospital 2012-12-31
NCT01464827 ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients https://ClinicalTrials.gov/show/NCT01464827 Completed AbbVie 2013-03-31
NCT01453075 Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I) https://ClinicalTrials.gov/show/NCT01453075 Completed VA Office of Research and Development 2015-07-31
NCT01439373 Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects https://ClinicalTrials.gov/show/NCT01439373 Completed GlaxoSmithKline 2011-12-05
NCT01433887 Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic Hepatitis C Genotypes 1 Versus 2/3 Versus 6 https://ClinicalTrials.gov/show/NCT01433887 Completed Third Affiliated Hospital, Sun Yat-Sen University 2014-06-30
NCT01425203 The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160) https://ClinicalTrials.gov/show/NCT01425203 Completed Merck Sharp & Dohme Corp. 2013-10-21
NCT01413360 The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis Patients https://ClinicalTrials.gov/show/NCT01413360 Completed Seoul National University Hospital 2013-12-31
NCT01379508 Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept https://ClinicalTrials.gov/show/NCT01379508 Completed Novartis 2015-12-10
NCT01378104 100% VS 80% Of Pegasys In Koreans With Chronic Hepatitis C (CHC) https://ClinicalTrials.gov/show/NCT01378104 Completed The Catholic University of Korea 2011-09-30
NCT01373684 PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients https://ClinicalTrials.gov/show/NCT01373684 Completed Foundation for Liver Research 2019-10-28
NCT01355289 Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501 https://ClinicalTrials.gov/show/NCT01355289 Completed Eisai Inc. 2014-02-28
NCT01337791 Efficacy, Safety and Tolerability of Telbivudine in HBeAg Positive Chronic Hepatitis B Pregnant Women With Elevated Alanine Aminotransferase Levels https://ClinicalTrials.gov/show/NCT01337791 Completed Southeast University, China 2009-12-31
NCT01326546 Therapeutic Hepatitis B Vaccine (Mimogen-based) Joint Entecavir in Treating Chronic Hepatitis B Patients https://ClinicalTrials.gov/show/NCT01326546 Completed Chongqing Jiachen Biotechnology Ltd. 2014-01-31
NCT01320943 Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB https://ClinicalTrials.gov/show/NCT01320943 Completed Gilead Sciences 2016-07-28
NCT04423393 Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection https://ClinicalTrials.gov/show/NCT04423393 Recruiting Vir Biotechnology, Inc. 2022-08-31
NCT04398134 A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection https://ClinicalTrials.gov/show/NCT04398134 Recruiting Assembly Biosciences 2023-01-19
NCT04387526 Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4 https://ClinicalTrials.gov/show/NCT04387526 Completed Beni-Suef University 2017-05-31
NCT04318379 Therapeutic Hepatitis C Virus Vaccine https://ClinicalTrials.gov/show/NCT04318379 Recruiting GeneCure Biotechnologies 2022-02-28
NCT04246723 Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1 https://ClinicalTrials.gov/show/NCT04246723 Recruiting R-Pharm 2022-01-01
NCT04201275 The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC74647 in HCV-infected Subjects https://ClinicalTrials.gov/show/NCT04201275 Completed Sunshine Lake Pharma Co., Ltd. 2020-01-17
NCT04198584 Study of Telemedicine Stress Management and Lifestyle Group Intervention for HCV Patients https://ClinicalTrials.gov/show/NCT04198584 Recruiting University of North Carolina, Chapel Hill 2021-01-15
NCT04195074 Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Chronic Hepatitis b https://ClinicalTrials.gov/show/NCT04195074 Recruiting Third Affiliated Hospital, Sun Yat-Sen University 2023-12-31
NCT04182321 Adding Metformin to the Standard Treatment for Patients With HBeAg-Negative Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT04182321 Recruiting Beijing 302 Hospital 2021-12-31
NCT04180150 A Study of TQ-A3334 Combined With Entecavir in the Treatment of Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT04180150 Recruiting Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 2020-09-30
NCT04157699 An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Tenofovir in Naive Patients With Chronic Hepatitis b https://ClinicalTrials.gov/show/NCT04157699 Recruiting Qilu Pharmaceutical Co., Ltd. 2020-12-31
NCT04157257 An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis b Who Have Received Nucleoside (Acid) Therapy https://ClinicalTrials.gov/show/NCT04157257 Recruiting Qilu Pharmaceutical Co., Ltd. 2020-12-31
NCT04112147 A Randomized, Placebo-controlled Trial of Antroquinonol in Patients With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT04112147 Recruiting Chung Shan Medical University 2020-06-30
NCT04102176 Halting Nucleoside Analogues in Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT04102176 Recruiting National University Health System, Singapore 2021-03-31
NCT04069858 Maintaining Antiviral Efficacy After Switching to Generic Entecavir 1 mg for Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT04069858 Active, not recruiting Korea University 2019-03-01
NCT03995485 KW-136 With Sofosbuvir for Chinese Adults With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT03995485 Completed Kawin Technology Share-holding Co., Ltd. 2018-01-25
NCT03905655 Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT03905655 Recruiting Romark Laboratories L.C. 2022-12-01
NCT03801798 A Study of GC1102(Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients https://ClinicalTrials.gov/show/NCT03801798 Active, not recruiting Green Cross Corporation 2021-12-31
NCT03801538 The Optimizing Treatment of Peginterferon Alpha in Chronic Hepatitis B Patients With Low Level HBsAg https://ClinicalTrials.gov/show/NCT03801538 Active, not recruiting Third Affiliated Hospital, Sun Yat-Sen University 2020-12-31
NCT03792919 Cessation of Long Term NAs vs. Keeping on NAs Among CHB Patients (CNAVK) https://ClinicalTrials.gov/show/NCT03792919 Recruiting Humanity & Health Medical Group Limited 2023-12-31
NCT03780543 A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients https://ClinicalTrials.gov/show/NCT03780543 Active, not recruiting Assembly Biosciences 2021-06-30
NCT03723824 Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation https://ClinicalTrials.gov/show/NCT03723824 Recruiting Taichung Veterans General Hospital 2021-11-30
NCT03714152 A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT03714152 Recruiting Assembly Biosciences 2020-08-31
NCT03672188 Study of VIR-2218 in Healthy Volunteers and Patients With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT03672188 Active, not recruiting Vir Biotechnology, Inc. 2021-03-31
NCT03638076 The Safety, Antiviral Activity, and Pharmacokinetics of Morphothiadine Mesilate Capsules https://ClinicalTrials.gov/show/NCT03638076 Recruiting Sunshine Lake Pharma Co., Ltd. 2018-12-09
NCT03615066 Safety, Tolerability, and Antiviral Activity of Selgantolimod in Viremic Adults With Chronic Hepatitis B Who Are Not Currently on Treatment https://ClinicalTrials.gov/show/NCT03615066 Active, not recruiting Gilead Sciences 2019-12-12
NCT03612973 Changes in Liver Fibrosis, Lipid Profile and Insulin Resistance in HCV Patients Who Received Antiviral Therapy https://ClinicalTrials.gov/show/NCT03612973 Recruiting Assiut University 2021-10-31
NCT03585322 APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT03585322 Recruiting Ascentage Pharma Group Inc. 2021-10-30
NCT03577171 A Study Evaluating ABI-H0731+ NUC vs NUC Alone for the Treatment of Viremic HBeAg-positive, CHB Patients https://ClinicalTrials.gov/show/NCT03577171 Completed Assembly Biosciences 2019-06-21
NCT03576066 A Study Evaluating ABI-H0731 as Adjunctive Therapy in Patients With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT03576066 Completed Assembly Biosciences 2019-07-05
NCT03575208 Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT03575208 Recruiting National Institutes of Health Clinical Center (CC) 2022-05-30
NCT03546621 A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D https://ClinicalTrials.gov/show/NCT03546621 Completed Hepatera Ltd. 2018-01-31
NCT03491553 Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Adults With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT03491553 Active, not recruiting Gilead Sciences 2019-03-22
NCT03490097 Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination https://ClinicalTrials.gov/show/NCT03490097 Completed Ain Shams University 2018-05-23
NCT03488485 Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model https://ClinicalTrials.gov/show/NCT03488485 Recruiting Postgraduate Institute of Medical Education and Research 2020-12-31
NCT03487848 Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection https://ClinicalTrials.gov/show/NCT03487848 Active, not recruiting Bristol-Myers Squibb 2018-10-11
NCT03485846 Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-NaÑ—ve Patients With Chronic Hepatitis C Genotype 1b https://ClinicalTrials.gov/show/NCT03485846 Completed R-Pharm 2018-08-29
NCT03483987 Re-treatment of HCV Following DAA Failure https://ClinicalTrials.gov/show/NCT03483987 Recruiting Sanjay Gandhi Postgraduate Institute of Medical Sciences 2021-01-09
NCT03481036 DAA Therapy in Pediatric Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT03481036 Recruiting Postgraduate Institute of Medical Education and Research 2020-12-31
NCT03439488 A Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation; After Multi-Day Dosing in Healthy Participants; and After Multiple (Ascending) Doses in Participants With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT03439488 Completed Alios Biopharma Inc. 2019-10-10
NCT03429439 Study on Effect of Intestinal Microbiota Transplantation in Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT03429439 Recruiting Zhongshan Hospital Xiamen University 2020-10-31
NCT01264367 A Study to Evaluate the Efficacy and Safety of Clevudine and Peg-interferon in Sequence Compared With Clevudine Alone in the Patients With HBeAg(+) Chronic Hepatitis B or Clevudine and Peg-interferon Sequential Treatment in Patients With Chronic Hepatitis B Who Have HBeAg(+) https://ClinicalTrials.gov/show/NCT01264367 Completed Bukwang Pharmaceutical 2013-08-31
NCT01264354 An Open Study to Evaluate the Efficacy, Safety of Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT01264354 Completed Bukwang Pharmaceutical 2012-08-31
NCT01260350 Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3 https://ClinicalTrials.gov/show/NCT01260350 Completed Gilead Sciences 2013-10-31
NCT01241760 VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT01241760 Completed Janssen Infectious Diseases BVBA 2012-08-31
NCT03434353 Study to Evaluate the Antiviral Activity of Inarigivir Soproxil (GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB) https://ClinicalTrials.gov/show/NCT03434353 Active, not recruiting Gilead Sciences 2020-01-20
NCT01225380 A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01225380 Completed Gilead Sciences 2013-01-31
NCT01221298 A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) https://ClinicalTrials.gov/show/NCT01221298 Completed AbbVie 2011-05-31
NCT01195181 Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice. https://ClinicalTrials.gov/show/NCT01195181 Completed Azienda Ospedaliera di Padova 2009-12-31
NCT01192854 An Study of Efficacy and Safety of Clevudine https://ClinicalTrials.gov/show/NCT01192854 Completed Eisai Inc. 2011-05-31
NCT01178996 Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin. https://ClinicalTrials.gov/show/NCT01178996 Completed sigma-tau i.f.r. S.p.A. 2008-05-31
NCT01144936 Study of VX-985 in Subjects With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01144936 Completed Vertex Pharmaceuticals Incorporated 2010-10-31
NCT01143662 Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT01143662 Completed Xiamen Amoytop Biotech Co., Ltd. 2011-04-30
NCT01140997 Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01140997 Completed Xiamen Amoytop Biotech Co., Ltd. 2011-01-31
NCT01121731 A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01121731 Completed Digna Biotech S.L. 2012-10-31
NCT01120795 Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy https://ClinicalTrials.gov/show/NCT01120795 Completed Melbourne Health 2006-01-31
NCT01113814 Acoustic Radiation Force Impulse-Imaging in Comparison to Transient Elastography for Liver Fibrosis Staging in HCV https://ClinicalTrials.gov/show/NCT01113814 Completed Johann Wolfgang Goethe University Hospital NA
NCT01098006 A Study in Adult Subjects With Chronic Hepatitis B Infection to Support the Development of Immunological Assays https://ClinicalTrials.gov/show/NCT01098006 Completed GlaxoSmithKline 2012-02-20
NCT01090232 Host Responses in Kidney-transplant Recipients With Chronic Hepatitis E Virus Infection https://ClinicalTrials.gov/show/NCT01090232 Completed Assistance Publique Hopitaux De Marseille 2012-02-29
NCT01088009 Efficacy Optimizing Research of Lamivudine Therapy https://ClinicalTrials.gov/show/NCT01088009 Completed Nanfang Hospital of Southern Medical University 2013-02-28
NCT01079806 A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection https://ClinicalTrials.gov/show/NCT01079806 Completed Bristol-Myers Squibb 2013-03-31
NCT01074008 A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 https://ClinicalTrials.gov/show/NCT01074008 Completed AbbVie 2011-06-30
NCT01063036 Efficacy and Safety Study of Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Who Failed Previous Treatment https://ClinicalTrials.gov/show/NCT01063036 Completed Bristol-Myers Squibb 2012-11-30
NCT01037166 Study in Japan of the Safety And Antiviral Activity in Adults With Chronic Hepatitis B Current Lamivudine Therapy https://ClinicalTrials.gov/show/NCT01037166 Completed Bristol-Myers Squibb 2005-02-28
NCT01037062 An Open-Label Rollover Study of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B Infection https://ClinicalTrials.gov/show/NCT01037062 Completed Bristol-Myers Squibb 2006-12-31
NCT01026610 Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT01026610 Completed LG Life Sciences 2010-11-30
NCT01023217 Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir https://ClinicalTrials.gov/show/NCT01023217 Completed Asan Medical Center 2012-07-31
NCT01022801 A Phase II Dose Response Study in Japan in Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT01022801 Completed Bristol-Myers Squibb 2005-03-31
NCT01020565 A Study in Japan of the Safety and Antiviral Activity With Chronic Hepatitis B Infection https://ClinicalTrials.gov/show/NCT01020565 Completed Bristol-Myers Squibb 2005-02-28
NCT01018615 Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01018615 Completed University of North Carolina, Chapel Hill 2013-04-30
NCT01012895 Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care https://ClinicalTrials.gov/show/NCT01012895 Completed Bristol-Myers Squibb 2012-10-31
NCT01011166 Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004) https://ClinicalTrials.gov/show/NCT01011166 Completed Merck Sharp & Dohme Corp. 2010-07-31
NCT00988767 Safety and Immunogenicity of a Naked DNA-based Vaccine Therapy in Patients With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00988767 Completed Institut National de la Santé Et de la Recherche Médicale, France 2003-11-30
NCT00983060 Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients https://ClinicalTrials.gov/show/NCT00983060 Completed Novartis 2011-04-30
NCT00975091 Continue Entecavir Rollover From China https://ClinicalTrials.gov/show/NCT00975091 Completed Bristol-Myers Squibb 2007-08-31
NCT00973817 Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis https://ClinicalTrials.gov/show/NCT00973817 Completed Vital Therapies, Inc. 2011-04-30
NCT00973219 Hepatitis B Surface Antigen(HBsAg) Loss in Chronic Hepatitis B Patients With Low Viral Load https://ClinicalTrials.gov/show/NCT00973219 Active, not recruiting Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 2019-11-30
NCT00968357 Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed https://ClinicalTrials.gov/show/NCT00968357 Completed SciClone Pharmaceuticals 2011-01-31
NCT00944684 High Dose Ribavirin in the Treatment of Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00944684 Completed University of Bern 2011-04-30
NCT00936715 Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States https://ClinicalTrials.gov/show/NCT00936715 Completed Gilead Sciences 2015-11-30
NCT00926016 Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant CHC GT 1 Subjects https://ClinicalTrials.gov/show/NCT00926016 Completed Brooke Army Medical Center 2010-03-31
NCT00909129 Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment https://ClinicalTrials.gov/show/NCT00909129 Completed Karolinska Institutet NA
NCT00907894 Pharmacokinetics and Safety of Single-Dose Telbivudine in Children and Adolescents With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00907894 Completed Novartis 2012-03-31
NCT00895596 Safety and Efficacy Study of LB80380 in the Patients With Lamivudine-Refractory Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00895596 Completed LG Life Sciences 2006-08-31
NCT00883844 PEG-IFN in HBV Patients With Incomplete Response to NA https://ClinicalTrials.gov/show/NCT00883844 Completed Foundation for Liver Research 2012-06-30
NCT00881582 Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients https://ClinicalTrials.gov/show/NCT00881582 Completed King Abdulaziz Medical City 2011-12-31
NCT00877760 Augmenting Response to Entecavir With Peginterferon a-2a for the Treatment of HBeAg-positive Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00877760 Completed Foundation for Liver Research 2013-07-31
NCT00877149 Efficacy of Telbivudine Treatment at Long Term on the Absence of Liver Inflammation in Patients With Compensated Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00877149 Completed Novartis 2011-04-30
NCT00869778 Phase 2 Trial of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00869778 Completed Chongqing Jiachen Biotechnology Ltd. 2011-11-30
NCT00857675 A Efficacy and Safety Study of Adefovir Dipivoxil to Treat Chinese Patients With HBeAg+ve Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00857675 Completed GlaxoSmithKline 2008-03-31
NCT00854802 A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients https://ClinicalTrials.gov/show/NCT00854802 Completed Debiopharm International SA 2010-09-30
NCT00854087 Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis https://ClinicalTrials.gov/show/NCT00854087 Completed SCTI Research Foundation 2013-04-30
NCT00851890 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection https://ClinicalTrials.gov/show/NCT00851890 Completed AbbVie 2009-07-31
NCT00844272 Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment https://ClinicalTrials.gov/show/NCT00844272 Completed Universitätsklinikum Hamburg-Eppendorf 2008-11-30
NCT02862106 Second Stage:Open-label Study of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT02862106 Completed Chongqing Jiachen Biotechnology Ltd. 2013-03-31
NCT00830609 High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 https://ClinicalTrials.gov/show/NCT00830609 Completed Hospital Universitario Fundación Alcorcón 2011-09-30
NCT00828269 Evaluation of RNA From the Liver Tissue Obtained in Patients With Chronic Hepatitis C (0000-123) https://ClinicalTrials.gov/show/NCT00828269 Completed Merck Sharp & Dohme Corp. 2010-02-28
NCT00823862 Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection https://ClinicalTrials.gov/show/NCT00823862 Completed Dynavax Technologies Corporation 2009-12-31
NCT03778567 Renoprotective Effects of Telbivudine in Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT03778567 Completed The University of Hong Kong 2016-06-16
NCT03501550 Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL) https://ClinicalTrials.gov/show/NCT03501550 Completed Cocrystal Pharma, Inc. 2019-01-08
NCT01524679 Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen https://ClinicalTrials.gov/show/NCT01524679 Completed Johannes Gutenberg University Mainz 2017-08-28
NCT00807001 Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects https://ClinicalTrials.gov/show/NCT00807001 Completed Merck Sharp & Dohme Corp. 2009-07-31
NCT00804622 Effects of Telbivudine and Tenofovir Disproxil Fumarate on the Kinetics of Hepatitis B Virus DNA in Chronic Hepatitis B (CHB) https://ClinicalTrials.gov/show/NCT00804622 Completed The University of Hong Kong 2009-06-30
NCT02979613 Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed https://ClinicalTrials.gov/show/NCT02979613 Completed Gilead Sciences 2018-09-10
NCT02642432 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis https://ClinicalTrials.gov/show/NCT02642432 Completed AbbVie 2016-10-27
NCT02637999 Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection https://ClinicalTrials.gov/show/NCT02637999 Completed Hepatera Ltd. 2016-01-21
NCT02636595 The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4) https://ClinicalTrials.gov/show/NCT02636595 Completed AbbVie 2016-10-31
NCT02579382 Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated https://ClinicalTrials.gov/show/NCT02579382 Completed Gilead Sciences 2017-01-16
NCT02027116 Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection https://ClinicalTrials.gov/show/NCT02027116 Completed GeneOne Life Science, Inc. 2015-07-31
NCT02123212 Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C https://ClinicalTrials.gov/show/NCT02123212 Completed National Opinion Research Center 2014-03-31
NCT00793793 Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced https://ClinicalTrials.gov/show/NCT00793793 Completed Boehringer Ingelheim 2011-01-31
NCT00790673 A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1 https://ClinicalTrials.gov/show/NCT00790673 Completed Can-Fite BioPharma 2011-06-30
NCT00788918 Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS) https://ClinicalTrials.gov/show/NCT00788918 Completed University of Aarhus 2012-11-30
NCT00782353 Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV Infection https://ClinicalTrials.gov/show/NCT00782353 Completed Hoffmann-La Roche 2009-03-31
NCT00781105 Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00781105 Completed Novartis 2010-09-16
NCT00780910 Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy https://ClinicalTrials.gov/show/NCT00780910 Completed Mitsubishi Tanabe Pharma Corporation 2010-10-31
NCT00778843 Antioxidant and Immunomodulator Properties of Viusid in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00778843 Completed Catalysis SL 2009-05-31
NCT00771446 Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic Insufficiency https://ClinicalTrials.gov/show/NCT00771446 Completed Vital Therapies, Inc. 2009-04-30
NCT00763568 4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00763568 Completed Romark Laboratories L.C. 2008-09-30
NCT00759200 Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients https://ClinicalTrials.gov/show/NCT00759200 Completed Novartis 2010-12-31
NCT00749138 Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy https://ClinicalTrials.gov/show/NCT00749138 Completed Bader, Ted, M.D. 2009-05-31
NCT00736190 A Study to Evaluate Tenofovir Disoproxil Fumarate (DF) in Asian-American Adults With Chronic Hepatitis B Infection https://ClinicalTrials.gov/show/NCT00736190 Completed Gilead Sciences 2010-07-31
NCT00735969 High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1 https://ClinicalTrials.gov/show/NCT00735969 Completed National Institutes of Health Clinical Center (CC) 2013-06-30
NCT00734162 Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection https://ClinicalTrials.gov/show/NCT00734162 Completed Gilead Sciences 2011-03-31
NCT00724776 Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients https://ClinicalTrials.gov/show/NCT00724776 Completed Novartis 2009-07-31
NCT00680342 Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment https://ClinicalTrials.gov/show/NCT00680342 Completed National Center for Complementary and Integrative Health (NCCIH) 2011-01-31
NCT00680173 Peripheral Blood Mononuclear Cell (PBMC) Gene Expression in HCV Genotype 1 Patients https://ClinicalTrials.gov/show/NCT00680173 Completed Kaohsiung Medical University Chung-Ho Memorial Hospital 2016-03-31
NCT00671671 Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus. https://ClinicalTrials.gov/show/NCT00671671 Completed Pfizer 2008-12-31
NCT00656006 A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3 https://ClinicalTrials.gov/show/NCT00656006 Completed Human Genome Sciences Inc. 2007-04-30
NCT00641082 A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function https://ClinicalTrials.gov/show/NCT00641082 Completed Bukwang Pharmaceutical 2012-03-31
NCT00630084 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma https://ClinicalTrials.gov/show/NCT00630084 Completed Kaohsiung Medical University Chung-Ho Memorial Hospital 2008-10-31
NCT00629967 A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients https://ClinicalTrials.gov/show/NCT00629967 Completed Kaohsiung Medical University Chung-Ho Memorial Hospital 2007-05-31
NCT00629824 Pegylated Interferon Plus Ribavirin in Treating Older Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00629824 Completed Kaohsiung Medical University Chung-Ho Memorial Hospital 2009-04-30
NCT00606086 Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection https://ClinicalTrials.gov/show/NCT00606086 Completed GlobeImmune 2012-11-30
NCT00596960 Study of the Effects of Motivational Enhancement Therapy on Alcohol Use in Chronic Hepatitis C Patients https://ClinicalTrials.gov/show/NCT00596960 Completed VA Office of Research and Development 2012-06-30
NCT00596414 Sedation and Analgesia for Transjugular Liver Biopsy: A Randomized Double Blind Placebo Controlled Trial https://ClinicalTrials.gov/show/NCT00596414 Completed Erasme University Hospital 2005-10-31
NCT00591214 Safety and PK Study of MP-424 to Treat Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00591214 Completed Mitsubishi Tanabe Pharma Corporation 2008-10-31
NCT00558493 Switching Study From Lamivudine to Clevudine in the Chronic Hepatitis B Patients https://ClinicalTrials.gov/show/NCT00558493 Completed Bukwang Pharmaceutical NA
NCT00546442 Treatment Insulin Resistence in HCV G-1 Patient https://ClinicalTrials.gov/show/NCT00546442 Completed Valme University Hospital NA
NCT00528528 An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants https://ClinicalTrials.gov/show/NCT00528528 Completed Tibotec BVBA 2009-07-31
NCT00540345 Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00540345 Completed Kaohsiung Medical University Chung-Ho Memorial Hospital 2013-12-31
NCT00536627 Efficacy and Tolerance of Naked DNA Vaccine in Patients With Chronic B Hepatitis https://ClinicalTrials.gov/show/NCT00536627 Completed French National Agency for Research on AIDS and Viral Hepatitis 2010-11-30
NCT00532701 Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR https://ClinicalTrials.gov/show/NCT00532701 Completed National Taiwan University Hospital 2014-03-31
NCT00531167 Adding Adefovir Dipivoxil Versus Switching to Entecavir in Patients With Lamivudine-resistant Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00531167 Completed Korea University 2011-04-30
NCT00530972 Pilot Study of Patients Chronic Hepatitis C in Co-infected HIV Patients Relapsers After Previous Therapies https://ClinicalTrials.gov/show/NCT00530972 Completed Hospital Carlos III, Madrid 2008-12-31
NCT00519792 Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior Treatment https://ClinicalTrials.gov/show/NCT00519792 Completed Intarcia Therapeutics 2010-03-31
NCT00513968 Phase I Study to Investigate the Safety and Efficacy of HBV DNA Vaccine https://ClinicalTrials.gov/show/NCT00513968 Completed Genexine, Inc. 2010-04-30
NCT00507689 Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant https://ClinicalTrials.gov/show/NCT00507689 Completed Gilead Sciences 2011-05-31
NCT00507507 A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT) https://ClinicalTrials.gov/show/NCT00507507 Completed Gilead Sciences 2012-02-29
NCT00503347 Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus https://ClinicalTrials.gov/show/NCT00503347 Completed Peregrine Pharmaceuticals 2011-03-31
NCT00502099 Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4 https://ClinicalTrials.gov/show/NCT00502099 Completed Ain Shams University 2009-05-31
NCT00502086 Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection. https://ClinicalTrials.gov/show/NCT00502086 Completed Catalysis SL 2009-07-31
NCT00491244 Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00491244 Completed National Taiwan University Hospital 2013-09-30
NCT00491179 Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin https://ClinicalTrials.gov/show/NCT00491179 Completed National Taiwan University Hospital 2008-06-30
NCT00487318 Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin https://ClinicalTrials.gov/show/NCT00487318 Completed Bader, Ted, M.D. 2010-10-31
NCT00475176 S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00475176 Completed National Institutes of Health Clinical Center (CC) 2011-05-31
NCT00467545 An Extension to Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00467545 Completed Novartis 2009-09-30
NCT00446134 Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV) https://ClinicalTrials.gov/show/NCT00446134 Completed Bausch Health Americas, Inc. 2008-04-30
NCT00445419 Phase I Hepatitis C Vaccine Trial of Virosome-formulated Peptides https://ClinicalTrials.gov/show/NCT00445419 Completed Pevion Biotech Ltd NA
NCT00441974 Adefovir Dipivoxil For The Treatment Of Chinese Compensated Chronic Hepatitis B(CHB)Patients https://ClinicalTrials.gov/show/NCT00441974 Completed GlaxoSmithKline 2008-09-30
NCT00433069 Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone https://ClinicalTrials.gov/show/NCT00433069 Completed University Hospital, Geneva 2007-12-31
NCT00423670 Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523) https://ClinicalTrials.gov/show/NCT00423670 Completed Merck Sharp & Dohme Corp. 2008-08-31
NCT00421434 Study of Nitazoxanide, Peginterferon, and Ribavirin Combination Therapies in the Treatment of Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00421434 Completed Romark Laboratories L.C. 2008-09-30
NCT00418639 Study of Nitazoxanide in the Treatment of Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00418639 Completed Romark Laboratories L.C. NA
NCT00418054 Study of Nitazoxanide Combined With Peginterferon Compared to Peginterferon Monotherapy in the Treatment of Hepatitis C https://ClinicalTrials.gov/show/NCT00418054 Completed Romark Laboratories L.C. NA
NCT00412529 Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00412529 Completed Novartis 2008-02-29
NCT00411385 Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3 https://ClinicalTrials.gov/show/NCT00411385 Completed Human Genome Sciences Inc. 2008-10-31
NCT00403585 Study of Adefovir Dipivoxil for Korean Patients With Chronic Hepatitis B(CHB) Who Have Completed ADF 103814 https://ClinicalTrials.gov/show/NCT00403585 Completed GlaxoSmithKline 2008-04-30
NCT00402428 Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients https://ClinicalTrials.gov/show/NCT00402428 Completed Human Genome Sciences Inc. 2009-02-28
NCT00395421 Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin https://ClinicalTrials.gov/show/NCT00395421 Completed Merck Sharp & Dohme Corp. 2008-06-30
NCT00395018 Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection https://ClinicalTrials.gov/show/NCT00395018 Completed Bristol-Myers Squibb 2011-03-31
NCT00393484 A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection https://ClinicalTrials.gov/show/NCT00393484 Completed Bristol-Myers Squibb 2009-01-31
NCT00354653 A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone https://ClinicalTrials.gov/show/NCT00354653 Completed ViiV Healthcare 2007-01-23
NCT00352235 Phase I/II Trial of KRN7000 in Patients With Chronic Hepatitis C Infection https://ClinicalTrials.gov/show/NCT00352235 Completed Foundation for Liver Research NA
NCT00347009 Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis https://ClinicalTrials.gov/show/NCT00347009 Completed GlaxoSmithKline 2009-09-30
NCT00338780 Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia) https://ClinicalTrials.gov/show/NCT00338780 Completed Chinese University of Hong Kong NA
NCT00324961 Adefovir Dipivoxil Tablets (10mg) In Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00324961 Completed GlaxoSmithKline 2009-01-31
NCT00316719 Adefovir Dipivoxil In Compensated Chronic Hepatitis B Patients https://ClinicalTrials.gov/show/NCT00316719 Completed GlaxoSmithKline 2008-01-31
NCT00307489 Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil https://ClinicalTrials.gov/show/NCT00307489 Completed Gilead Sciences 2008-01-31
NCT00307242 Study Comparing the Safety of Switching From Lamivudine to Adefovir Dipivoxil Versus Overlapping Lamivudine and Adefovir Before Adefovir Dipivoxil Monotherapy in Patients With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00307242 Completed Thomas Jefferson University NA
NCT00304551 A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC) https://ClinicalTrials.gov/show/NCT00304551 Completed Chugai Pharmaceutical 2009-12-31
NCT00299936 Comparison of PEG-Intron and Two Different Doses of Ribavirin for the Treatment of Chronic Hepatitis C In Treatment Naïve Subjects https://ClinicalTrials.gov/show/NCT00299936 Completed Weill Medical College of Cornell University NA
NCT00298714 Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00298714 Completed Hospital Clinic of Barcelona NA
NCT00298363 Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease. https://ClinicalTrials.gov/show/NCT00298363 Completed Gilead Sciences 2011-04-30
NCT00291616 Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00291616 Completed Seoul National University Hospital 2008-08-31
NCT00287235 Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS) https://ClinicalTrials.gov/show/NCT00287235 Completed Baxter Healthcare Corporation 2003-11-30
NCT00277862 Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4 https://ClinicalTrials.gov/show/NCT00277862 Completed Ain Shams University 2007-03-31
NCT00277576 Safety Study of HBV DNA Vaccine to Treat Patients With Chronic Hepatitis B Infection https://ClinicalTrials.gov/show/NCT00277576 Completed PowderMed NA
NCT00277238 CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects https://ClinicalTrials.gov/show/NCT00277238 Completed Pfizer 2007-07-31
NCT00275938 Interferon Alpha 2b Plus Ribavirin for Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00275938 Completed National Taiwan University Hospital NA
NCT00262379 Use or Non-use of Epoetin Beta in Patients Infected by Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00262379 Completed University Hospital, Angers 2009-06-30
NCT00249860 A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects https://ClinicalTrials.gov/show/NCT00249860 Completed EMD Serono 2005-08-31
NCT00245414 Trial of Pegasys® in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00245414 Completed Chugai Pharmaceutical 2010-07-31
NCT00230958 Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment-Naive https://ClinicalTrials.gov/show/NCT00230958 Completed Bausch Health Americas, Inc. 2006-01-31
NCT00230854 Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin https://ClinicalTrials.gov/show/NCT00230854 Completed OPKO Health, Inc. NA
NCT00227435 Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00227435 Completed Merck Sharp & Dohme Corp. 2004-07-31
NCT00226447 Different Regimens of Pegylated Interferon and Lamivudine Combination Therapy in Chronic Hepatitis B Patients https://ClinicalTrials.gov/show/NCT00226447 Completed Chinese University of Hong Kong 2006-07-31
NCT00226382 Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment https://ClinicalTrials.gov/show/NCT00226382 Completed Chinese University of Hong Kong 2008-04-30
NCT00215891 PEG-Interferon a-2b + Ribavirin for Treatment of Chronic HRN 005 Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon https://ClinicalTrials.gov/show/NCT00215891 Completed Hepatitis Resource Network NA
NCT00215865 PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy https://ClinicalTrials.gov/show/NCT00215865 Completed Hepatitis Resource Network NA
NCT00200343 Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00200343 Completed Mitsubishi Tanabe Pharma Corporation NA
NCT00199719 Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C. CINAM https://ClinicalTrials.gov/show/NCT00199719 Completed University Hospital, Limoges NA
NCT00196664 Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus Ribavirin https://ClinicalTrials.gov/show/NCT00196664 Completed French National Agency for Research on AIDS and Viral Hepatitis NA
NCT00196586 Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients https://ClinicalTrials.gov/show/NCT00196586 Completed French National Agency for Research on AIDS and Viral Hepatitis NA
NCT00172809 Interferon Treatment for Patients With Chronic Hepatitis C and End Stage Renal Disease https://ClinicalTrials.gov/show/NCT00172809 Completed National Taiwan University Hospital 2006-06-30
NCT00162734 Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy https://ClinicalTrials.gov/show/NCT00162734 Completed Bausch Health Americas, Inc. 2007-06-30
NCT00160251 Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED) https://ClinicalTrials.gov/show/NCT00160251 Completed Merck Sharp & Dohme Corp. 2007-07-31
NCT00158496 Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211) https://ClinicalTrials.gov/show/NCT00158496 Completed French National Agency for Research on AIDS and Viral Hepatitis NA
NCT00146016 Study on Chronic Hepatitis C Treatment With Interferon Alpha, Ribavirin and Amantadine in Naive Patients https://ClinicalTrials.gov/show/NCT00146016 Completed UMC Utrecht NA
NCT00144469 A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00144469 Completed Chugai Pharmaceutical NA
NCT00142298 Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies https://ClinicalTrials.gov/show/NCT00142298 Completed Novartis 2009-11-30
NCT00142103 CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus (HCV) Subjects https://ClinicalTrials.gov/show/NCT00142103 Completed Pfizer 2007-02-28
NCT00140725 Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV) https://ClinicalTrials.gov/show/NCT00140725 Completed GlaxoSmithKline NA
NCT00132652 Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00132652 Completed Novartis 2006-12-31
NCT00131742 Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00131742 Completed Novartis 2007-01-31
NCT00117676 A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00117676 Completed Gilead Sciences 2007-04-30
NCT00120861 Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy https://ClinicalTrials.gov/show/NCT00120861 Completed Merck Sharp & Dohme Corp. NA
NCT00120835 Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C https://ClinicalTrials.gov/show/NCT00120835 Completed Merck Sharp & Dohme Corp. NA
NCT00118768 A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C https://ClinicalTrials.gov/show/NCT00118768 Completed Merck Sharp & Dohme Corp. NA
NCT00116805 A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00116805 Completed Gilead Sciences 2007-05-31
NCT00115245 Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00115245 Completed Novartis 2006-08-31
NCT00107653 Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1. https://ClinicalTrials.gov/show/NCT00107653 Completed Hoffmann-La Roche 2007-09-30
NCT00100659 PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C https://ClinicalTrials.gov/show/NCT00100659 Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 2008-08-31
NCT00096785 Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection https://ClinicalTrials.gov/show/NCT00096785 Completed Bristol-Myers Squibb 2006-01-31
NCT00095121 Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00095121 Completed Gilead Sciences 2006-05-31
NCT00093093 Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive https://ClinicalTrials.gov/show/NCT00093093 Completed Bausch Health Americas, Inc. 2006-05-31
NCT00086541 Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy https://ClinicalTrials.gov/show/NCT00086541 Completed Bausch Health Americas, Inc. NA
NCT00084279 CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders) https://ClinicalTrials.gov/show/NCT00084279 Completed InterMune NA
NCT02476617 Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults https://ClinicalTrials.gov/show/NCT02476617 Completed AbbVie 2016-08-31
NCT00071201 Evaluate Efficacy, Safety and PK of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00071201 Completed Gilead Sciences 2006-03-31
NCT00057265 A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00057265 Completed Novartis 2006-04-30
NCT00049842 Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED) https://ClinicalTrials.gov/show/NCT00049842 Completed Merck Sharp & Dohme Corp. 2009-10-31
NCT00048945 Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00048945 Completed Hoffmann-La Roche 2004-10-31
NCT00036608 A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine https://ClinicalTrials.gov/show/NCT00036608 Completed Bristol-Myers Squibb 2005-02-28
NCT00035789 A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen https://ClinicalTrials.gov/show/NCT00035789 Completed Bristol-Myers Squibb 2005-05-31
NCT00035633 A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E Antigen https://ClinicalTrials.gov/show/NCT00035633 Completed Bristol-Myers Squibb 2005-02-28
NCT00028275 Gamma Interferon Therapy for Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00028275 Completed National Institutes of Health Clinical Center (CC) NA
NCT00028093 Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease https://ClinicalTrials.gov/show/NCT00028093 Completed National Institutes of Health Clinical Center (CC) 2010-06-30
NCT00023309 Lamivudine and Adefovir to Treat Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00023309 Completed National Institutes of Health Clinical Center (CC) 2010-04-30
NCT00001729 Combination Drug Therapy for Patients With Hepatitis C https://ClinicalTrials.gov/show/NCT00001729 Completed National Institutes of Health Clinical Center (CC) NA
NCT00687999 NIDDM and IR in Combination Therapy for CHC https://ClinicalTrials.gov/show/NCT00687999 Completed Kaohsiung Medical University Chung-Ho Memorial Hospital 2008-06-30
NCT00048724 Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569) https://ClinicalTrials.gov/show/NCT00048724 Completed Merck Sharp & Dohme Corp. 2008-04-30
NCT00023153 Lamivudine and Adefovir to Treat Chronic Hepatitis B Infection in People With and Without HIV Infection https://ClinicalTrials.gov/show/NCT00023153 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001854 Long-Term Therapy With Ribavirin for Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00001854 Completed National Institutes of Health Clinical Center (CC) 2007-10-10
NCT00001457 Lamivudine for Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00001457 Completed National Institutes of Health Clinical Center (CC) NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT04208035 Hepatitis C Elimination in the Netherlands https://ClinicalTrials.gov/show/NCT04208035 Recruiting Radboud University 2021-01-01
NCT03346941 Side Effects After Direct-acting Antiviral Treatment https://ClinicalTrials.gov/show/NCT03346941 Completed Hospices Civils de Lyon 2017-09-30
NCT03329820 Quality of Life and Health Utility of Patients With CHB Infections https://ClinicalTrials.gov/show/NCT03329820 Completed The University of Hong Kong 2009-06-30
NCT03313154 Impact on QoL and Cognitive Functioning of New Antiviral Therapies in Subjects With Chronic Hepatitis HCV-related https://ClinicalTrials.gov/show/NCT03313154 Completed Azienda Ospedaliero Universitaria di Cagliari 2018-07-31
NCT03303599 Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6 https://ClinicalTrials.gov/show/NCT03303599 Completed AbbVie 2020-01-24
NCT03215732 Cross Sectional Survey on the Burden and Impacts of Chronic Hepatitis B in the Rural Area of Niakhar, Senegal https://ClinicalTrials.gov/show/NCT03215732 Completed French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) 2019-07-31
NCT03088917 ‘Fibrosis in the Lost Hepatitis C Population - Track, Trace and Treat’ https://ClinicalTrials.gov/show/NCT03088917 Completed Radboud University 2019-12-01
NCT03063723 Dynamic Changes of Monocytes and NK Cells of CHC Patient Treated by DAAs https://ClinicalTrials.gov/show/NCT03063723 Completed Third Affiliated Hospital, Sun Yat-Sen University 2016-12-01
NCT03053180 Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation https://ClinicalTrials.gov/show/NCT03053180 Completed AbbVie 2017-12-18
NCT03002818 Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®) https://ClinicalTrials.gov/show/NCT03002818 Completed AbbVie 2018-04-25
NCT02863757 Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease https://ClinicalTrials.gov/show/NCT02863757 Recruiting Humanity and Health Research Centre 2026-12-31
NCT02851069 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Colombia https://ClinicalTrials.gov/show/NCT02851069 Completed AbbVie 2018-08-30
NCT02817594 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02817594 Completed AbbVie 2018-03-07
NCT02807402 Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Romania https://ClinicalTrials.gov/show/NCT02807402 Completed AbbVie 2017-08-04
NCT02803138 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02803138 Completed AbbVie 2018-10-21
NCT02799355 Treatment of Chronic Hepatitis With Sofosbuvir in Combination With Ribavirin With or Without Pegylated Interferon: North India Gastroenterology Consortium https://ClinicalTrials.gov/show/NCT02799355 Completed Dayanand Medical College and Hospital 2016-09-30
NCT02788682 Association of Vitamin D Binding Protein Polymorphisms With Response to HCV Therapy https://ClinicalTrials.gov/show/NCT02788682 Completed Cairo University 2015-07-31
NCT02725866 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02725866 Completed AbbVie 2017-10-31
NCT02714712 SR-BI and Antiviral Treatment Response in HCV https://ClinicalTrials.gov/show/NCT02714712 Completed Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation 2016-07-31
NCT02669940 Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation https://ClinicalTrials.gov/show/NCT02669940 Completed AbbVie 2017-07-04
NCT02640547 Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02640547 Completed AbbVie 2017-03-29
NCT02636608 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary https://ClinicalTrials.gov/show/NCT02636608 Completed AbbVie 2018-05-23
NCT02618928 The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France https://ClinicalTrials.gov/show/NCT02618928 Completed AbbVie 2018-03-29
NCT02615145 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C) https://ClinicalTrials.gov/show/NCT02615145 Completed AbbVie 2018-03-26
NCT02595710 Bartonella in Liver Transplant Patients https://ClinicalTrials.gov/show/NCT02595710 Recruiting University of Minnesota 2020-12-31
NCT02582671 The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland https://ClinicalTrials.gov/show/NCT02582671 Completed AbbVie 2017-11-29
NCT02582658 Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL) https://ClinicalTrials.gov/show/NCT02582658 Completed AbbVie 2017-01-12
NCT02581189 Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada https://ClinicalTrials.gov/show/NCT02581189 Completed AbbVie 2017-12-20
NCT02545335 Neutrophil Function During Therapy With Protease Inhibitors in Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02545335 Active, not recruiting Medical University of Graz 2020-12-31
NCT02533544 Treatment Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in naïve Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT02533544 Completed The Catholic University of Korea 2018-10-31
NCT02508090 Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus Ribavirin https://ClinicalTrials.gov/show/NCT02508090 Completed Hoffmann-La Roche 2017-01-13
NCT02387463 Efficacy of Extended Peginterferon Alpha 2a Treatment in HBeAg Positive Chronic Hepatitis B Patients https://ClinicalTrials.gov/show/NCT02387463 Completed Beijing Ditan Hospital 2017-05-21
NCT02106156 Observational Study Evaluating the Quality of Pegylated Interferon Alfa-2a and Ribavirin Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists) https://ClinicalTrials.gov/show/NCT02106156 Completed Hoffmann-La Roche 2013-09-30
NCT02069678 Serum Hepatitis B Surface Antigen Levels to Guide the Stopping of Entecavir in HBeAg-negative Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT02069678 Completed Chinese University of Hong Kong 2013-09-30
NCT02065999 Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients https://ClinicalTrials.gov/show/NCT02065999 Recruiting Kirby Institute 2022-04-30
NCT01311947 Hepatitis B Virus Mutants and the Therapeutic Effect of Peginterferon Alfa-2a in HBeAg-Positive Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT01311947 Completed China Medical University Hospital 2012-03-31
NCT01310205 Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV https://ClinicalTrials.gov/show/NCT01310205 Completed SciClone Pharmaceuticals 2012-03-31
NCT02006823 Patient Self-management and Gene Guided Therapy for Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02006823 Completed Duke University 2014-07-31
NCT02005146 Retrospective Observational Study to Define HBsAg Loss With or Without Seroconversion to antiHBs in Patients With Chronic Hepatitis by B Virus Treated With Nucleoside/Nucleotide Analogs https://ClinicalTrials.gov/show/NCT02005146 Completed Andalusian Network for Design and Translation of Advanced Therapies 2014-12-31
NCT01980290 Telaprevir With Peginterferon Alfa & Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01980290 Completed Janssen Pharmaceutica N.V., Belgium 2015-02-28
NCT01958229 Efficacy Study of Telbivudine in Chronic Hepatitis B Patients https://ClinicalTrials.gov/show/NCT01958229 Completed National Taiwan University Hospital 2012-03-31
NCT01850745 Multidisciplinary Support Program in Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01850745 Completed Parc de Salut Mar 2009-01-31
NCT01826760 Study of the Model to Predict 3-month Mortality Risk of Acute-on-chronic Hepatitis B Liver Failure https://ClinicalTrials.gov/show/NCT01826760 Completed Wenzhou Medical University 2010-05-31
NCT01634919 Histologic Changes and Noninvasive Assessment in Hepatitis C Patients Treated With Peginterferon Alpha-2a and Ribavirin https://ClinicalTrials.gov/show/NCT01634919 Completed Seoul National University Boramae Hospital 2017-02-17
NCT01581554 Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT01581554 Completed National Institutes of Health Clinical Center (CC) NA
NCT01531166 A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon https://ClinicalTrials.gov/show/NCT01531166 Completed Yonsei University 2014-08-31
NCT01464008 The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01464008 Completed Beijing Ditan Hospital 2011-05-31
NCT01453244 Pharmacogenomic Research in Korean Patients With Hepatitis C https://ClinicalTrials.gov/show/NCT01453244 Completed Inje University 2013-03-31
NCT01402583 Menopause is a Critical Factor in Determining Failure of Antiviral Therapy in Women With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01402583 Completed University of Modena and Reggio Emilia 2011-08-31
NCT01323452 Entecavir for Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT01323452 Completed Foundation for Liver Research 2011-01-31
NCT04330508 Effects of Direct-acting Antiviral Agents on HCV Cognitive Function, and Depression in HCV Related Cirrhosis: A Prospective Clinical Trial https://ClinicalTrials.gov/show/NCT04330508 Recruiting Postgraduate Institute of Medical Education and Research 2020-10-31
NCT04214028 A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus https://ClinicalTrials.gov/show/NCT04214028 Recruiting AbbVie 2024-12-30
NCT04189627 A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation https://ClinicalTrials.gov/show/NCT04189627 Recruiting AbbVie 2021-03-01
NCT04170452 Study the Content of the HBV DNA in Liver Biopsy in the Patients Chronic Hepatitis Delta https://ClinicalTrials.gov/show/NCT04170452 Enrolling by invitation Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan 2020-06-01
NCT04160897 Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis https://ClinicalTrials.gov/show/NCT04160897 Enrolling by invitation Ruijin Hospital 2020-10-31
NCT04135235 Effect and Safety of Propofol Fumarate for Mother-to-child Blocking of Hepatitis B https://ClinicalTrials.gov/show/NCT04135235 Recruiting Beijing Ditan Hospital 2021-08-01
NCT04071353 Observational Cohort Study of Clinical Outcomes After Antiviral Therapy for Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT04071353 Recruiting Beijing Ditan Hospital 2020-08-01
NCT04032275 Correlation Between Virus and Biochemical Characteristics and Liver Histological Damage in Untreated Chronic HBV Infection https://ClinicalTrials.gov/show/NCT04032275 Completed Beijing Ditan Hospital 2018-12-30
NCT04030039 Cohort Study of Clinical Outcomes in Chronic HBV Infection Patients With Low HBsAg Under Unplanned Intervention https://ClinicalTrials.gov/show/NCT04030039 Recruiting Beijing Ditan Hospital 2020-12-30
NCT04028856 Cohort Study of Efficacy and Safety of Interferon Intermittent Treatment of Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT04028856 Completed Beijing Ditan Hospital 2019-06-30
NCT03993925 Enhancing Access to Care for Chronic Hepatitis C Infected Populations in Hong Kong https://ClinicalTrials.gov/show/NCT03993925 Recruiting The University of Hong Kong 2020-09-30
NCT03868163 Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C in the Russian Federation https://ClinicalTrials.gov/show/NCT03868163 Active, not recruiting AbbVie 2020-08-15
NCT03777969 Prediction System of Clinical Endpoint Events for Chronic Hepatitis B Patients https://ClinicalTrials.gov/show/NCT03777969 Recruiting Beijing Friendship Hospital 2020-12-31
NCT03752658 TAF Real World Study for Universal Effectiveness https://ClinicalTrials.gov/show/NCT03752658 Recruiting Tongji Hospital 2023-05-01
NCT03740230 An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs https://ClinicalTrials.gov/show/NCT03740230 Recruiting AbbVie 2022-09-30
NCT03693586 Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients Attended Primarily for Vasculitis https://ClinicalTrials.gov/show/NCT03693586 Recruiting Hospital General de Mexico 2020-05-01
NCT03643172 Terminator 2 Register https://ClinicalTrials.gov/show/NCT03643172 Recruiting Hannover Medical School 2020-07-31
NCT03587467 Study on Gut Microbiota in Chronic HBV Infected Patients https://ClinicalTrials.gov/show/NCT03587467 Recruiting Zhongshan Hospital Xiamen University 2020-12-01
NCT03559790 Treatment Efficacy and Safety of TDF-TAF Switch Study in South Korea https://ClinicalTrials.gov/show/NCT03559790 Recruiting The Catholic University of Korea 2020-08-31
NCT03510637 “Real Life” Evaluation of Efficacy and Safety of Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis C Virus in Egypt https://ClinicalTrials.gov/show/NCT03510637 Recruiting French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) 2020-08-31
NCT03500562 Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC) https://ClinicalTrials.gov/show/NCT03500562 Recruiting Bristol-Myers Squibb 2021-12-31
NCT01264107 An Open Study to Evaluate the Sustained Effect in Patients Showing Virological Responses With Muscle-related Symptom of Chronic Hepatitis B Patients Who Received Clevudine https://ClinicalTrials.gov/show/NCT01264107 Completed Bukwang Pharmaceutical 2012-01-31
NCT01163240 Epidemiological Study in Children and Adolescents With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT01163240 Completed Novartis 2011-09-30
NCT01159613 Do Low High Density Lipoprotein (HDL) Levels Predict Treatment Outcome in Patients With Chronic Hepatitis C Viral Infection? https://ClinicalTrials.gov/show/NCT01159613 Completed Ziv Hospital 2008-10-31
NCT00970216 Study of Telbivudine in Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00970216 Completed Chang Gung Memorial Hospital 2016-01-31
NCT00913757 A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area https://ClinicalTrials.gov/show/NCT00913757 Completed National Institutes of Health Clinical Center (CC) 2020-05-01
NCT03042481 Off-therapy Response After Stopping Entecavir or Tenofovir https://ClinicalTrials.gov/show/NCT03042481 Recruiting Kaohsiung Medical University Chung-Ho Memorial Hospital 2019-05-31
NCT02581163 Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium https://ClinicalTrials.gov/show/NCT02581163 Completed AbbVie 2018-02-12
NCT02798315 Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study https://ClinicalTrials.gov/show/NCT02798315 Completed AbbVie 2017-06-12
NCT02578693 Follow up of IFN Vs DAAs HCV SVR (IFDACS Study) https://ClinicalTrials.gov/show/NCT02578693 Recruiting Humanity and Health Research Centre 2020-12-31
NCT00736242 Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584) https://ClinicalTrials.gov/show/NCT00736242 Completed Merck Sharp & Dohme Corp. 2011-12-31
NCT00645736 CHARM: Chronic Hepatitis B Antihepadnaviral Resistance Mutation Study https://ClinicalTrials.gov/show/NCT00645736 Completed Gilead Sciences 2008-10-31
NCT00466336 Prediction of Hepatic Fibrosis in Patients With Chronic Hepatitis C by Biochemical and Duplex Doppler Indices https://ClinicalTrials.gov/show/NCT00466336 Completed National Taiwan University Hospital 2006-12-31
NCT00466271 Prediction of Significant Hepatic Fibrosis in HCV Carriers With PNALT by SAPI- A Validation Study https://ClinicalTrials.gov/show/NCT00466271 Completed National Taiwan University Hospital 2008-11-30
NCT00388674 Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection https://ClinicalTrials.gov/show/NCT00388674 Completed Bristol-Myers Squibb 2016-10-26
NCT00361179 Long Term Effects of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/B Co-Infection and Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00361179 Completed National Taiwan University Hospital NA
NCT00322179 Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00322179 Completed Palo Alto Veterans Institute for Research 2007-11-30
NCT00263614 Evaluation of Chronic HBV Patients w/Evidence of HBV Replication and Normal or Minimally Elevated Liver Transaminases. https://ClinicalTrials.gov/show/NCT00263614 Completed Gilead Sciences NA
NCT00199732 Evaluation of cccDNA and Total HBV DNA Kinetics in Lymphocytes, Total Blood and Serum in Chronic Hepatitis B Patients Treated With Adefovir Dipivoxil and Peg Interferon Alpha 2a https://ClinicalTrials.gov/show/NCT00199732 Completed University Hospital, Limoges 2009-07-31
NCT00187473 Natural History of Hepatitis C in Patients With Normal Liver Tests https://ClinicalTrials.gov/show/NCT00187473 Active, not recruiting University of California, San Francisco 2020-12-31

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02263755 Establishment of Retrospective and Prospective Multicenter Cohort for Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT02263755 Completed Yonsei University 2015-06-25
NCT02250001 Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02250001 Completed Bristol-Myers Squibb 2017-01-20
NCT02031913 Prospective Cohort Study of Association of Insulin Resistance/Steatosis With Hepatic Fibrosis in CHB and NAFLD https://ClinicalTrials.gov/show/NCT02031913 Recruiting Seoul National University Boramae Hospital 2022-11-30
NCT04301882 An Observational Cohort Study of Clinical Outcomes After Antiviral Treatment of Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT04301882 Recruiting Beijing Ditan Hospital 2020-09-01
NCT04211844 Metabolic Changes in Chronic HCV Patients Receiving DAAS https://ClinicalTrials.gov/show/NCT04211844 Recruiting Ain Shams University 2020-04-30
NCT04139850 The Establishment of Korean Hepatitis B Patients Cohort https://ClinicalTrials.gov/show/NCT04139850 Recruiting Yonsei University 2026-08-31
NCT04025944 Real World Study of Chronic Viral Hepatitis https://ClinicalTrials.gov/show/NCT04025944 Recruiting Huashan Hospital 2024-08-01
NCT03734783 IL-35+Breg/Il-35 Effect on T Cell Immune in Patients With CHB https://ClinicalTrials.gov/show/NCT03734783 Completed Changhai Hospital 2019-11-15
NCT03597633 Tenofovir Combination or Mono-therapy for MDR CHB https://ClinicalTrials.gov/show/NCT03597633 Active, not recruiting Korea University 2018-12-31
NCT01679769 Prospective Study In Noninvasive Evaluation of Hepatic Fibrosis in Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT01679769 Completed Peking University First Hospital 2015-10-31